Show simple item record

dc.contributor.authorvan Deursen, A M M
dc.contributor.authorSchurink-Van't Klooster, T M
dc.contributor.authorMan, W H
dc.contributor.authorvan de Kassteele, J
dc.contributor.authorvan Gageldonk-Lafeber, A B
dc.contributor.authorBruijning-Verhagen, P C J L
dc.contributor.authorde Melker, H E
dc.contributor.authorSanders, E A M
dc.contributor.authorKnol, M J
dc.date.accessioned2018-04-05T07:04:51Z
dc.date.available2018-04-05T07:04:51Z
dc.date.issued2017
dc.identifier.citationImpact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands. 2017, 35 (51):7107-7113 Vaccineen
dc.identifier.issn1873-2518
dc.identifier.pmid29146381
dc.identifier.doi10.1016/j.vaccine.2017.10.090
dc.identifier.urihttp://hdl.handle.net/10029/621757
dc.description.abstractThe long-term impact of pneumococcal conjugate vaccines on pneumonia hospitalizations in all age-groups varies between countries. In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV7) was implemented for newborns in 2006 and replaced by PCV10 in 2011. We assessed the impact of PCVs on community-acquired pneumonia (CAP) hospitalization rates in all age-groups.
dc.language.isoenen
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.titleImpact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.en
dc.typeArticleen
dc.identifier.journalVaccine 2017; 35(51):7107-13en
html.description.abstractThe long-term impact of pneumococcal conjugate vaccines on pneumonia hospitalizations in all age-groups varies between countries. In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV7) was implemented for newborns in 2006 and replaced by PCV10 in 2011. We assessed the impact of PCVs on community-acquired pneumonia (CAP) hospitalization rates in all age-groups.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record